ConductScience.org, home

Paper40697666

CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects.

Han H and 5 others. Front Pharmacol, 2025. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects. Papers, record 40697666. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40697666

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CRISPR/Cas9 technology in tumor research and drug development application progress and future prospects.
PubMed
Journal
Front Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
3.78, provisional
iCite
Revised in PubMed
2025-07-25
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Han HHan
2Sun XXiaoyan
3Guo XXiaoyun
4Wen JJiaxin
5Zhao XXiaoming
6Zhou WWeiqiang

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References178

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123979020Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.Cell Res2013https://conductscience.org/library/papers/23979020PubMed
236638795An evolved AAV variant enables efficient genetic engineering of murine T cells.Cell2023https://conductscience.org/library/papers/36638795PubMed
336856111CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer.J Clin Invest2023https://conductscience.org/library/papers/36856111PubMed
435953673High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects.Nat Biotechnol2023https://conductscience.org/library/papers/35953673PubMed
524433414Comparative analysis of RNAi screening technologies at genome-scale reveals an inherent processing inefficiency of the plasmid-based shRNA hairpin.Comb Chem High Throughput Screen2014https://conductscience.org/library/papers/24433414PubMed
626360417CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection.PLoS One2015https://conductscience.org/library/papers/26360417PubMed
719933107Breaking the code of DNA binding specificity of TAL-type III effectors.Science2009https://conductscience.org/library/papers/19933107PubMed
835619054Paired guide RNA CRISPR-Cas9 screening for protein-coding genes and lncRNAs involved in transdifferentiation of human B-cells to macrophages.BMC Genomics2022https://conductscience.org/library/papers/35619054PubMed
927956228Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.Gastroenterology2017https://conductscience.org/library/papers/27956228PubMed
1030155824Non-transgenic Approach to Deliver ZFNs in Seeds for Targeted Genome Engineering.Methods Mol Biol2018https://conductscience.org/library/papers/30155824PubMed
1126968626
Use of the MS2 aptamer and coat protein for RNA localization in yeast: A response to "MS2 coat proteins bound to yeast mRNAs block 5' to 3' degradation and trap mRNA decay products: implications for the localization of mRNAs by MS2-MCP system".
RNA2016https://conductscience.org/library/papers/26968626PubMed
1239103848BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.Mol Cancer2024https://conductscience.org/library/papers/39103848PubMed
1339426588CRISPR innovations in tissue engineering and gene editing.Life Sci2024https://conductscience.org/library/papers/39426588PubMed
1437239814Engineering Human Cells Expressing CRISPR/Cas9-Synergistic Activation Mediators for Recombinant Protein Production.Int J Mol Sci2023https://conductscience.org/library/papers/37239814PubMed
1532219447Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.Blood2020https://conductscience.org/library/papers/32219447PubMed
1634954490CRISPR/Cas9-mediated demethylation of FOXP3-TSDR toward Treg-characteristic programming of Jurkat T cells.Cell Immunol2022https://conductscience.org/library/papers/34954490PubMed
1725730490Highly efficient Cas9-mediated transcriptional programming.Nat Methods2015https://conductscience.org/library/papers/25730490PubMed
1830923225Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution.Science2019https://conductscience.org/library/papers/30923225PubMed
1936502574Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.EBioMedicine2023https://conductscience.org/library/papers/36502574PubMed
2034079130Base editing of haematopoietic stem cells rescues sickle cell disease in mice.Nature2021https://conductscience.org/library/papers/34079130PubMed

See all 178 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42893140Peptide-Mediated Precise Intracellular Delivery of Bioactive Substances.Int J Nanomedicine2026https://conductscience.org/library/papers/42893140PubMed
42539480CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions.Front Oncol2026https://conductscience.org/library/papers/42539480PubMed
42473674Genomic innovations in cancer prevention, diagnosis, prognosis and precision therapeutics.Front Genet2026https://conductscience.org/library/papers/42473674PubMed
42455481Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies.Mol Diagn Ther2026https://conductscience.org/library/papers/42455481PubMed
42135732Construction of a novel signature based on CRISPR-Cas9 screening for prognostic prediction in breast cancer.BMC Cancer2026https://conductscience.org/library/papers/42135732PubMed
41756253RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.MedComm (2020)2026https://conductscience.org/library/papers/41756253PubMed
41595749Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential.Biomedicines2026https://conductscience.org/library/papers/41595749PubMed
41252108Mitochondrial-Based Nanomedicine in Treatment of Liver Cancer.Mol Biotechnol2026https://conductscience.org/library/papers/41252108PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40697666

GET https://conductscience.org/api/papers/v1/40697666/references?page=2